ADAnnie Delaunois

Annie Delaunois

*This is an algorithmically generated author record based on publicly available information.

Annie Delaunois has a total of 200 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    25 years of applying the 3Rs principles in safety pharmacology: success stories and future perspectives

    by Katayoun Derakhchan, Kimberly Rockley, Matthias Gossmann, Raafat Fares, Eric Delpy, Yasunari Kanda, Elisa Passini, Colleen M. Pike, Janette Turner, Annie Delaunois

    Safety pharmacology is a relatively young discipline dedicated to identifying adverse pharmacodynamic effects of new drugs that may impact human safety. Since the publication of the ICH S7A guideline in 2000, the field has made significant efforts in implementing the 3Rs principles—Replacement, Reduction, and Refinement of animal use. This review provides a comprehensive overview of key milestones and innovations that have shaped the application of the 3Rs in safety pharmacology over the past 25 years. Typical examples are the use of non-invasive jacket telemetry for real-time cardiovascular monitoring in conscious freely moving animals and the introduction of the CiPA (Comprehensive in Vitro Proarrhythmia Assessment) paradigm in 2014. The review explores 3Rs-driven advances across core organ systems—cardiovascular, central nervous, and respiratory—as well as supplemental systems including gastrointestinal and renal. Furthermore, it examines the evolving global regulatory landscape and the emergence of new approach methodologies (NAMs), such as artificial intelligence tools and complex microphysiological systems (MPS), and their integration into drug development pipelines. Finally, the review discusses future directions and potential challenges in achieving broader adoption of 3Rs-compliant strategies and NAMs in safety pharmacology.


  • Current practices on the measurement of electrocardiogram and hemodynamic parameters in non–rodent species in regulatory safety assessment studies

    by Jean-Pierre Valentin, Todd Bourcier, Xuan Chi, Annie Delaunois, C. Michael Foley, Kim A. Henderson, Pierre Lainee, Derek J. Leishman, Dingzhou Li, Emma Pawluk, et al.


  • Data-driven federated learning in drug discovery with knowledge distillation

    by Thierry Hanser, Ernst Ahlberg, Alexander Amberg, Lennart T. Anger, Chris Barber, Richard J. Brennan, Alessandro Brigo, Annie Delaunois, Susanne Glowienke, Nigel Greene, et al.


  • Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarials

    by Annie Delaunois, Alvaro Cardenas, Teresa de Haro, Helga H J Gerets, Vitalina Gryshkova, Simon Hebeisen, Chloé Korlowski, Benoit Laleu, Martin A Lowe, Jean-Pierre Valentin

    Quinoline-related antimalarial drugs have been associated with cardiotoxicity risk, in particular QT prolongation and QRS complex widening. In collaboration with Medicines for Malaria Venture, we discovered novel plasmepsin X (PMX) inhibitors for malaria treatment. The first lead compounds tested in anesthetized guinea pigs (GPs) induced profound QRS widening, although exhibiting weak inhibition of NaV1.5-mediated currents in standard patch clamp assays. To understand the mechanism(s) underlying QRS widening to identify further compounds devoid of such liability, we established a set of in vitro models including CaV1.2, NaV1.5 rate-dependence, and NaV1.8 patch clamp assays, human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM), and Langendorff-perfused isolated GP hearts. Six compounds were tested in all models including anesthetized GP, and 8 additional compounds were tested in vitro only. All compounds tested in anesthetized GP and isolated hearts showed a similar cardiovascular profile, consisting of QRS widening, bradycardia, negative inotropy, hypotension, and for some, QT prolongation. However, a left shift of the concentration–response curves was noted from in vitro to in vivo GP data. When comparing in vitro models, there was a good consistency between decrease in sodium spike amplitude in hiPSC-CM and QRS widening in isolated hearts. Patch clamp assay results showed that the QRS widening observed with PMX inhibitors is likely multifactorial, primarily due to NaV1.8 and NaV1.5 rate-dependent sodium blockade and/or calcium channel-mediated mechanisms. In conclusion, early de-risking of QRS widening using a set of different in vitro assays allowed to identify novel PMX inhibitors with improved cardiac safety profile.


  • Assessing the interplay between off-target promiscuity, cytotoxicity, and tolerability in rodents to improve the safety profile of novel anti-malarial plasmepsin X inhibitors

    by Helga H J Gerets, Annie Delaunois, Alvaro Cardenas, Reiner Class, Renaud Fleurance, Teresa de Haro, Benoît Laleu, Martin A Lowe, Marie-Luce Rosseels, Jean-Pierre Valentin

    Within drug development, high off-target promiscuity as well as potent cytotoxicity, are associated with a high attrition rate. We investigated the safety profile of novel plasmepsin X (PMX) inhibitors for the treatment of malaria. In our screening cascade, a total of 249 PMX compounds were profiled in a panel of in vitro secondary pharmacology assays containing 44 targets (SafetyScreen44™ panel) and in a cytotoxicity assay in HepG2 cells using ATP as an endpoint. Six of the lead compounds were subsequently tested in a 7-day rat toxicology study, and/or in a cardiovascular study in guinea pigs. Overall, compounds with high cytotoxicity in HepG2 cells correlated with high promiscuity (off-target hit rate >20%) in the SafetyScreen44™ panel and were associated with poor tolerability in vivo (decedents, morbidity, adverse clinical signs, or severe cardiovascular effects). Some side effects observed in rats or guinea pigs could putatively be linked with hits in the secondary pharmacological profiling, such as the M1 or M2 muscarinic acetylcholine receptor, opioid µ and/or κreceptors or hERG/CaV1.2/Na+ channels, which were common to > 50% the compounds tested in vivo. In summary, compounds showing high cytotoxicity and high promiscuity are likely to be poorly tolerated in vivo. However, such associations do not necessarily imply a causal relationship. Identifying the targets that cause these undesirable effects is key for early safety risk assessment. A tiered approach, based on a set of in vitro assays, helps selecting the compounds with highest likelihood of success to proceed to in vivo toxicology studies.


  • Open Access

    Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicines

    by Richard J. Brennan, Stephen Jenkinson, Andrew Brown, Annie Delaunois, Bérengère Dumotier, Malar Pannirselvam, Mohan Rao, Lyn Rosenbrier Ribeiro, Friedemann Schmidt, Alicia Sibony, et al.


  • Top Cited Papers

    The state of the art in secondary pharmacology and its impact on the safety of new medicines

    by Richard J. Brennan, Stephen Jenkinson, Andrew Brown, Annie Delaunois, Bérengère Dumotier, Malar Pannirselvam, Mohan Rao, Lyn Rosenbrier Ribeiro, Friedemann Schmidt, Alicia Sibony, et al.

    Secondary pharmacology screening of investigational small-molecule drugs for potentially adverse off-target activities has become standard practice in pharmaceutical research and development, and regulatory agencies are increasingly requesting data on activity against targets with recognized adverse effect relationships. However, the screening strategies and target panels used by pharmaceutical companies may vary substantially. To help identify commonalities and differences, as well as to highlight opportunities for further optimization of secondary pharmacology assessment, we conducted a broad-ranging survey across 18 companies under the auspices of the DruSafe leadership group of the International Consortium for Innovation and Quality in Pharmaceutical Development. Based on our analysis of this survey and discussions and additional research within the group, we present here an overview of the current state of the art in secondary pharmacology screening. We discuss best practices, including additional safety-associated targets not covered by most current screening panels, and present approaches for interpreting and reporting off-target activities. We also provide an assessment of the safety impact of secondary pharmacology screening, and a perspective on opportunities and challenges in this rapidly developing field.


  • Results from a Joined Prospective Study to Evaluate the Sensitivity of the In Vivo Dog QT Assay in Line with the ICH E14/S7B Q&A Best Practices

    by Anne‐Marie Bétat, Annie Delaunois, Eric Delpy, Mathilde Loiseau, Anne Maurin, Gwendoline Poizat, Celine Possémé, Ferdinand Weinelt, Christophe Drieu la Rochelle, Eric Martel, et al.

    The ICH E14/S7B Q&As highlighted the need for best practices concerning the design, execution, analysis, interpretation, and reporting of the in vivo non‐rodent QT assay as a component of the integrated risk assessment to potentially support a TQT waiver or substitute. We conducted a dog telemetry study to assess the effects on QTc of six reference compounds (five positive and one negative) previously evaluated by Darpo et al. (2015) in humans. The sensitivity of the assay to detect QTc increases was determined, and exposure–response analysis was performed, as done in clinical practice. By‐timepoint analysis showed QTc prolongation induced by moxifloxacin, dofetilide, dolasetron, ondansetron, and quinine within human relevant plasma exposures ranges. Moreover, a hysteresis was observed for quinine. As expected, levocetirizine showed no statistically significant effect on QTc across a range of exposure, well exceeding the therapeutic Cmax. Power analyses confirmed the study ability to detect statistically significant QTc changes of less than 10 milliseconds with 80% probability, even with a sample size as low as n = 4 animals. Finally, concentration‐QTc modeling enabled to predict the minimal plasma concentration needed to detect a 10 milliseconds QTc prolongation, including for quinine. The comparison with clinical available data supported the relevance of dogs under these experimental conditions as a robust translational predictor of drug‐induced QTc prolongation in humans as a key pillar of the integrated risk assessment.


  • Open Access

    Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study

    by Annie Delaunois, François‐Xavier Mathy, Miranda Cornet, Vitalina Gryshkova, Chloé Korlowski, François Bonfitto, Juliane Koch, Anne‐Françoise Schlit, Simon Hebeisen, Elisa Passini, et al.

    Levetiracetam (LEV), a well‐established anti‐seizure medication (ASM), was launched before the original ICH S7B nonclinical guidance assessing QT prolongation potential and the introduction of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm. No information was available on its effects on cardiac channels. The goal of this work was to “pressure test” the CiPA approach with LEV and check the concordance of nonclinical core and follow‐up S7B assays with clinical and post‐marketing data. The following experiments were conducted with LEV (0.25–7.5 mM): patch clamp assays on hERG (acute or trafficking effects), NaV1.5, CaV1.2, Kir2.1, KV7.1/mink, KV1.5, KV4.3, and HCN4; in silico electrophysiology modeling (Virtual Assay® software) in control, large‐variability, and high‐risk human ventricular cell populations; electrophysiology measurements in human induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes and dog Purkinje fibers; ECG measurements in conscious telemetered dogs after single oral administration (150, 300, and 600 mg/kg). Except a slight inhibition (V7.1/mink at 7.5 mM, that is, 30‐fold the free therapeutic plasma concentration (FTPC) at 1500 mg, LEV did not affect any other cardiac channels or hERG trafficking. In both virtual and real human cardiomyocytes, and in dog Purkinje fibers, LEV induced no relevant changes in electrophysiological parameters or arrhythmia. No QTc prolongation was noted up to 2.7 mM unbound plasma levels in conscious dogs, corresponding to 10‐fold the FTPC. Nonclinical assessment integrating CiPA assays shows the absence of QT prolongation and proarrhythmic risk of LEV up to at least 10‐fold the FTPC and the good concordance with clinical and postmarketing data, although this does not exclude very rare occurrence of QT prolongation cases in patients with underlying risk factors.


  • Open Access

    Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362

    by Martin A. Lowe, Alvaro Cardenas, Jean-Pierre Valentin, Zhaoning Zhu, Jan Abendroth, Jose L. Castro, Reiner Class, Annie Delaunois, Renaud Fleurance, Helga Gerets, et al.

    Plasmepsin X (PMX) is an essential aspartyl protease controlling malaria parasite egress and invasion of erythrocytes, development of functional liver merozoites (prophylactic activity), and blocking transmission to mosquitoes, making it a potential multistage drug target. We report the optimization of an aspartyl protease binding scaffold and the discovery of potent, orally active PMX inhibitors with in vivo antimalarial efficacy. Incorporation of safety evaluation early in the characterization of PMX inhibitors precluded compounds with a long human half-life (t1/2) to be developed. Optimization focused on improving the off-target safety profile led to the identification of UCB7362 that had an improved in vitro and in vivo safety profile but a shorter predicted human t1/2. UCB7362 is estimated to achieve 9 log 10 unit reduction in asexual blood-stage parasites with once-daily dosing of 50 mg for 7 days. This work demonstrates the potential to deliver PMX inhibitors with in vivo efficacy to treat malaria.